MedPath

Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2
Terminated
Conditions
Lung Cancer
Interventions
Registration Number
NCT00118131
Lead Sponsor
University of Medicine and Dentistry of New Jersey
Brief Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving docetaxel together with cisplatin works in treating patients with stage III or stage IV non-small cell lung cancer.

Detailed Description

OBJECTIVES:

Primary

* Determine the antitumor activity of docetaxel and cisplatin, as measured by tumor response rate, in patients with chemotherapy-naïve stage IIIB or IV non-small cell lung cancer.

Secondary

* Determine the duration of response in patients treated with this regimen.

* Determine time to disease progression in patients treated with this regimen.

* Determine the 1-year survival rate in patients treated with this regimen.

* Determine the median survival time in patients treated with this regimen.

* Correlate aneuploidy (as determined by DNA histograms) and immunohistochemical expression of stathmin, Aurora-A, and survivin with response in patients treated with this regimen.

OUTLINE: This is an open-label, nonrandomized, multicenter study.

Patients receive docetaxel IV over 1 hour and cisplatin IV over 1 hour once on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 6 months.

PROJECTED ACCRUAL: A total of 76 patients will be accrued for this study within 13-19 months.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
49
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Docetaxel and CisplatincisplatinA cycle is defined as an interval of 28 days. Docetaxel, 35 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 105 mg/m2). Cisplatin, 25 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 75 mg/m2). Docetaxel is always to be given prior to cisplatin on Days 1, 8 and 15.
Docetaxel and CisplatindocetaxelA cycle is defined as an interval of 28 days. Docetaxel, 35 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 105 mg/m2). Cisplatin, 25 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 75 mg/m2). Docetaxel is always to be given prior to cisplatin on Days 1, 8 and 15.
Primary Outcome Measures
NameTimeMethod
Overall Tumor Response Rate7 years

Patients experiencing complete or partial response. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.", or similar definition that is accurate and appropriate.

Secondary Outcome Measures
NameTimeMethod
1-year Survival Rate1 year
Median Survival Time10 years
Time to Progressive Disease8 years

Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Trial Locations

Locations (13)

UMDNJ - University Hospital

🇺🇸

Newark, New Jersey, United States

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School

🇺🇸

New Brunswick, New Jersey, United States

JFK Medical Center in Edison

🇺🇸

Edison, New Jersey, United States

Raritan Bay Medical Center

🇺🇸

Perth Amboy, New Jersey, United States

Central Jersey Oncology Center, PA - East Brunswick

🇺🇸

East Brunswick, New Jersey, United States

CentraState Medical Center

🇺🇸

Freehold, New Jersey, United States

Cancer Institute of New Jersey at Hamilton

🇺🇸

Hamilton, New Jersey, United States

Monmouth Medical Center

🇺🇸

Long Branch, New Jersey, United States

Jersey Shore University Medical Center

🇺🇸

Neptune, New Jersey, United States

Saint Peter's University Hospital

🇺🇸

New Brunswick, New Jersey, United States

Mountainside Hospital Cancer Center

🇺🇸

Montclair, New Jersey, United States

Somerset Medical Center

🇺🇸

Somerville, New Jersey, United States

Overlook Hospital

🇺🇸

Summit, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath